S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:SRNE

Sorrento Therapeutics (SRNE) Price Target & Analyst Ratings

$0.12
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.12
▼
$0.13
50-Day Range
$0.12
▼
$0.40
52-Week Range
$0.16
▼
$3.09
Volume
3.12 million shs
Average Volume
52.69 million shs
Market Capitalization
$56.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Sorrento Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

$9.00
7,469.39% Upside
High Prediction$13.00
Average Prediction$9.00
Low Prediction$5.00
TypeCurrent
9/25/22 to 9/25/23		1 Month Ago
8/26/22 to 8/26/23		3 Months Ago
6/27/22 to 6/27/23		1 Year Ago
9/25/21 to 9/25/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$9.00$9.00$9.00$20.00
Predicted Upside7,469.39% Upside556.93% Upside556.93% Upside693.65% Upside
Get Sorrento Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.


SRNE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SRNE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Sorrento Therapeutics Stock vs. The Competition

TypeSorrento TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.65
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside2,828.73% Upside636.05% Upside20.98% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/13/2023Dawson James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral
1/31/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$20.00 ➝ $13.00+1,268.41%
11/2/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		B. Folkes
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageOverweight$5.00+216.45%
(Data available from 9/25/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












SRNE Price Target - Frequently Asked Questions

What is Sorrento Therapeutics's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Sorrento Therapeutics stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for SRNE. The average twelve-month price prediction for Sorrento Therapeutics is $9.00 with a high price target of $13.00 and a low price target of $5.00. Learn more on SRNE's analyst rating history.

Do Wall Street analysts like Sorrento Therapeutics more than its competitors?

Analysts like Sorrento Therapeutics less than other Medical companies. The consensus rating score for Sorrento Therapeutics is 2.50 while the average consensus rating score for medical companies is 2.66. Learn more on how SRNE compares to other companies.

Does Sorrento Therapeutics's stock price have much upside?

According to analysts, Sorrento Therapeutics's stock has a predicted upside of 556.93% based on their 12-month price targets.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:SRNE) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -